Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Placebo-Outcome'

Placebo-Outcome published presentations and documents on DocSlides.

Phase 2 Trial Evaluating the Effect of Dexpramipexole on Eosinophil Biomarkers and Lung Function in
Phase 2 Trial Evaluating the Effect of Dexpramipexole on Eosinophil Biomarkers and Lung Function in
by thomas
Professor Salman Siddiqui, Clinical Professor of A...
Deciding to Participate in Research
Deciding to Participate in Research
by jasmine
The Pros and Cons. Natalie Diaz, MD. Pacific Neuro...
The Northeast ALS Consortium
The Northeast ALS Consortium
by unita
Merit E. Cudkowicz, MD, MSc. Mass General Hospital...
Landmark statin trials a
Landmark statin trials a
by hadly
cross . the . spectrum . of . risk. : . Secondary ...
J. Brady Scott, MSc , RRT-ACCS
J. Brady Scott, MSc , RRT-ACCS
by pagi
Assistant Professor . Department of Respiratory Ca...
Dr Krishnadas. N C​ Associate Professor Neurology, MES Medical College
Dr Krishnadas. N C​ Associate Professor Neurology, MES Medical College
by emma
​. DM Neurology (2011-2014) - Government Medical...
analysis of the control groups in doubleblind trials of medicines dem
analysis of the control groups in doubleblind trials of medicines dem
by joy
broad variation 0 to 100 percent placebo effective...
European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4
European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4
by jasmine
ICH Topic E 10 Choice of Control Group in Clinical...
According to template WWCLINER102SD02 VERSION N02 05OCT2007Thes
According to template WWCLINER102SD02 VERSION N02 05OCT2007Thes
by ceila
Study centers The study was conducted in 25 cente...
Dupixent is indicated for the treatment of moderatetosevere atopic d
Dupixent is indicated for the treatment of moderatetosevere atopic d
by bella
First targeted biologic for adults with moderate-t...
HIGHLIGHTSOFPRESCRIBINGINFORMATIONThesehighlightsdonotincludealltheinf
HIGHLIGHTSOFPRESCRIBINGINFORMATIONThesehighlightsdonotincludealltheinf
by sadie
Notforthereliefofacutebronchospasmorstatusasthmati...
JAPIVOL 52MARCH 2004wwwjapiorg231
JAPIVOL 52MARCH 2004wwwjapiorg231
by stella
Update ArticleBiologics in Rheumatoid ArthritisP K...
HIGHLIGHTSOFPRESCRIBINGINFORMATIONThesehighlightsdonotincludealltheinf
HIGHLIGHTSOFPRESCRIBINGINFORMATIONThesehighlightsdonotincludealltheinf
by byrne
Notforthereliefofacutebronchospasmorstatusasthmati...
Submitter Name: Marta Ceko
Submitter Name: Marta Ceko
by jasmine
PI Name: Tor D. WagerPI email: tor.wager@colorado....
New Insights from EXSCEL
New Insights from EXSCEL
by pongre
M. Angelyn Bethel, MD. Associate Professor of Diab...
EDUCATIONAL SLIDE MODULES
EDUCATIONAL SLIDE MODULES
by dsuser1
Module D: . Evaluating CV safety and potential for...
Management of Dementia:
Management of Dementia:
by maniakiali
Pharmacologic and Non-Pharmacologic . Approaches. ...
Edward Fox, MD, PhD Phase 2 Multicenter Study Results of
Edward Fox, MD, PhD Phase 2 Multicenter Study Results of
by medmacr
Ublituximab. , a Novel Glycoengineered Anti-CD20 M...
Long -Term Efficacy of Dapagliflozin in T2DM Patients Receiving
Long -Term Efficacy of Dapagliflozin in T2DM Patients Receiving
by vamput
High-Dose Insulin. John . P.H. . Wilding, DM, FRCP...
Best of ASCO GU Session Sandy Srinivas.MD
Best of ASCO GU Session Sandy Srinivas.MD
by experimentgoogle
Stanford University. Outline. Abstract #4. :. . I...
PPAR  activation Clinical
PPAR  activation Clinical
by maniakti
evidence. Evolution of clinical evidence supportin...
AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSIONS 2019
AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSIONS 2019
by yoshiko-marsland
AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSION...
ETHICAL ASPECTS of
ETHICAL ASPECTS of
by cheryl-pisano
ETHICAL ASPECTS of PLACEBO SURGERY AAOS ETHICS ...
Apixaban vs VKA and
Apixaban vs VKA and
by cheryl-pisano
Apixaban vs VKA and Aspirin vs Placebo in Patie...
Trial Design Evolocumab SC
Trial Design Evolocumab SC
by danika-pritchard
140 mg Q2W or 420 mg QM. Placebo SC. Q2W or QM. L...
UB Dept of Neurology UBMD Neurology/JNI
UB Dept of Neurology UBMD Neurology/JNI
by alida-meadow
brains. &GAINS. November 2, 2013. 9-12 a.m.. ...
How Do We Treat Obesity?
How Do We Treat Obesity?
by karlyn-bohler
Weight Loss Medications. 2. 3. Phentermine. 4. DE...
Asthma: A Highly Prevalent and Often Inadequately Controlled Disease
Asthma: A Highly Prevalent and Often Inadequately Controlled Disease
by lois-ondreau
1. Centers for Disease Control and Prevention (CD...
Planning for Retirement: Depression
Planning for Retirement: Depression
by debby-jeon
Richard C. Shelton, M.D.. James G. Blakemore Rese...
How Do We Treat Obesity?
How Do We Treat Obesity?
by liane-varnes
Weight Loss Medications. 2. 3. Phentermine. 4. DE...
Update on Treatment of Myasthenia Gravis
Update on Treatment of Myasthenia Gravis
by conchita-marotz
KUMC Neurology Grand Rounds. 07/29/2016. Richard...
1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery
1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery
by mitsue-stanley
Dr. PJ Devereaux on behalf of POISE. Investigato...
Kenneth W. Mahaffey, MD,
Kenneth W. Mahaffey, MD,
by cheryl-pisano
on behalf of the TRACER Investigators and Committ...
Medications for Obesity Management
Medications for Obesity Management
by aaron
Faisal . saeed. , MD.. Advocate weight Management...
Eating Behavior Defect: Consequences and New treatment Modalities
Eating Behavior Defect: Consequences and New treatment Modalities
by lois-ondreau
Charles SAAB MD / CEHP / MAACE . Consultant Endo...
New Drug Update 2016 A Formulary Approach
New Drug Update 2016 A Formulary Approach
by test
J. Russell May, Pharm.D., FASHP. Clinical Profess...
Comparison of Adherence among Partners’ PrEP Participants on Placebo before and after Release of
Comparison of Adherence among Partners’ PrEP Participants on Placebo before and after Release of
by briana-ranney
B. Wamuti. , J. Odoyo, B. Rono, C. Cohen, E. Buku...
Pravastatin in Elderly Individuals at Risk of Vascular Dise
Pravastatin in Elderly Individuals at Risk of Vascular Dise
by min-jolicoeur
Presented at Late Breaking Clinical Trials. AHA 2...
Placebo + PR
Placebo + PR
by aaron
W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastro...
The Safety and Tolerability of CSL112, a Reconstituted, Inf
The Safety and Tolerability of CSL112, a Reconstituted, Inf
by faustina-dinatale
A. poA. -I . E. vent reducin. G. in . I. schemic...